Novavax, Inc.

NASDAQ (USD): Novavax, Inc. (NVAX)

Last Price

7.83

Today's Change

+0.51 (6.96%)

Day's Change

7.36 - 8.01

Trading Volume

6,789,329

Overview

Market Cap

1 Billion

Shares Outstanding

160 Million

Avg Volume

6,396,885

Avg Price (50 Days)

11.26

Avg Price (200 Days)

10.03

PE Ratio

-3.59

EPS

-2.18

Earnings Announcement

12-Nov-2024

Previous Close

7.32

Open

7.40

Day's Range

7.3663 - 8.01

Year Range

3.53 - 23.86

Trading Volume

6,789,329

Price Change Highlight

1 Day Change

6.97%

5 Day Change

0.38%

1 Month Change

-23.08%

3 Month Change

-43.67%

6 Month Change

-39.82%

Ytd Change

55.67%

1 Year Change

37.37%

3 Year Change

-95.93%

5 Year Change

108.80%

10 Year Change

-91.91%

Max Change

-90.21%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment